• Nonsteroidal MRAs: Will finerenone take the throne?

    11 days ago - By Healio

    Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial outcomes in several renin-angiotensin-aldosterone system-mediated disease states.
    Consensus guidelines in hypertension, diabetes and chronic kidney disease recommend mineralocorticoid receptor antagonists for resistant hypertension to reduce albuminuria and provide CV benefit. MRAs are also recommended to prevent mortality and adverse CV outcomes in HF with reduced ejection fraction and, more recently, HF with mildly reduced, improved or preserved EF.
    Until recently,
    Read more ...